Edison Investment Research - GLG Life Tech Corp. (GLG.) Update: Q314 results light, looking ahead

Report

Edison Investment Research

Update: Q314 results light, looking ahead

Q314 results were below our expectations and we are reducing 2014 and 2015 estimates. We retain confidence in GLGâ€™s prospects, as growth in deployment of its high extract-yielding Huinong 3 (H3) leaf and the start of Luo Han Guo (LHG) extract sales in Q414 should improve margins. Recent stevia pricing increases may help GLG return to positive EBITDA in 2016.

12/12/2014 8 EN

Underlying

GLG Life Tech Corp.

GLG Life Tech is a vertically integrated producer of stevia extract, an all-natural sweetener extracted from the stevia plant. Co. is engaged in the research and development, growing, refining and production of stevia extract for distribution to the global food and beverage industry.

See profile

CA3617932015 Toronto Stock Exchange Canada

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

Ford Equity Research

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stockâ€™s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the we...

EUR 18.48

December 16, 2016 December 16, 2016 2 EN

Edison Investment Research

Update: Termination of coverage

Edison Investment Research is terminating coverage on GLG Life Tech Corp. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

September 29, 2015 September 29, 2015 1 EN

Edison Investment Research

Update: Luo Han Guo drives revenue growth

While Q215 stevia revenue was below our forecasts, net results matched our expectations of an adjusted C$0.11 EPS loss. We expect margins to improve in the coming quarters, through increased LHG sales and overall capacity utilisation, and the deployment of higher extract-yielding proprietary stevia leaf. We continue to anticipate GLG will reach break-even EBITDA in 2016 and generate positive operating income in 2017.

September 23, 2015 September 23, 2015 6 EN

Record - AUME momentum and a sharper focus

Record’s Q424 trading update demonstrated continued growth in assets under management equivalent (AUME), which will support management fee growth into FY25. In FY24, AUME grew 17% to US$102.2bn, setting a new milestone in business scale. Net inflows for FY24 were US$6.8bn (FY23: US$9.1bn) or 8% of opening AUME. Performance fees of US$5.8m matched the record FY23 figure, and we expect this to offset the negative product mix in FY24. We have reduced our FY24e EPS by 1%, which is affected by £2.4bn in IT restructuring and impairment charges announced in March 2024. New CEO Dr Jan Witte is putting...

13h / 48m 13h / 48m 1 EN

Sean Conroy

Sean Conroy

Actinogen Medical - Funding in place through key catalysts

Actinogen announced a capital increase of up to A$8.9m on 3 May, consisting of a A$5.0m (gross) placement along with a shareholder rights offering (‘entitlement offer’) designed to raise up to A$3.9m (gross) from existing shareholders. The closing date of the rights offer is 29 May and, given that Actinogen shares are currently trading at c A$0.028, we assume full exercise of the rights offering in Q424 (Q2 CY24). The company expects that the proceeds (assuming full exercise of the rights offering) will extend its operating runway beyond the interim results release of the first 100 patients of...

May 15, 2024 May 15, 2024 1 EN

Pedro Fonseca

Pedro Fonseca

Henderson Opportunities Trust - A differentiated exposure to smaller companies

With a focus on long-term growth, Henderson Opportunities Trust (HOT) seeks investment opportunities across the breadth of the UK market. This includes a strong bias towards smaller and earlier-stage companies with significant potential to become tomorrow’s leading British businesses. There are tentative signs that the significant three-year underperformance of these smaller companies, and of HOT, may be coming to an end. If so, the trust is well placed to benefit and its differentiated, truly all-market approach is one that many investors would struggle to replicate. Moreover, HOT’s size and ...

May 15, 2024 May 15, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Update: Q314 results light, looking ahead

Ford Equity International Rating and Forecast Report

Update: Termination of coverage

Update: Luo Han Guo drives revenue growth

Record - AUME momentum and a sharper focus

Actinogen Medical - Funding in place through key catalysts

Henderson Opportunities Trust - A differentiated exposure to smaller companies

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe